Chu, Da-Tong
Chinese University of Hong Kong · Chinese Academy of Medical Sciences & Peking Union Medical College · Guangdong General Hospital · AstraZeneca (Japan) · Cancer Hospital of Chinese Academy of Medical Sciences · State Key Laboratory of Oncology in South China · Kindai University
2 papers on CoChat
Most cited papers
- Verified
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 8,261
- Verified
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 1,581
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free